XGN EXAGEN INC revenue, earnings and financials

For the quarter ended June 30, 2026, EXAGEN INC reported revenue of $19.9M (up 15.9% from a year earlier), net income of −$3.20M and diluted EPS of −$0.13; over the last four quarters revenue was $71.1M and net income −$18.9M; for the fiscal year ended December 2025 revenue was $66.6M, up 19.7% on the year before.

XGN annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $66.6M, gross profit $38.8M, operating income −$14.1M, net income −$20.0M (margin -30.0%), EPS −$0.93
• Fiscal year ended Dec 2024: revenue $55.6M, gross profit $33.1M, operating income −$13.6M, net income −$15.1M (margin -27.2%), EPS −$0.83
• Fiscal year ended Dec 2023: revenue $52.5M, gross profit $29.5M, operating income −$22.8M, net income −$23.7M (margin -45.1%), EPS −$1.34
• Fiscal year ended Dec 2022: revenue $45.6M, gross profit n/a, operating income −$46.1M, net income −$47.4M (margin -104.0%), EPS −$2.77
• Fiscal year ended Dec 2021: revenue $48.3M, gross profit n/a, operating income −$24.1M, net income −$26.9M (margin -55.6%), EPS −$1.68

XGN quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $19.9M (up 15.9% year over year), net income −$3.20M, EPS −$0.13
• Quarter ended Mar 31, 2026: revenue $17.3M (up 11.7% year over year), net income −$3.97M, EPS −$0.17
• Quarter ended Dec 31, 2025 (from the annual report): revenue $16.6M (up 21.8% year over year), net income −$4.67M, EPS −$0.21
• Quarter ended Sep 30, 2025: revenue $17.2M (up 37.9% year over year), net income −$7.09M, EPS −$0.31
• Quarter ended Jun 30, 2025: revenue $17.2M (up 14.2% year over year), net income −$4.44M, EPS −$0.21
• Quarter ended Mar 31, 2025: revenue $15.5M (up 7.5% year over year), net income −$3.75M, EPS −$0.20
• Quarter ended Dec 31, 2024 (from the annual report): revenue $13.7M (down 0.8% year over year), net income −$3.76M, EPS −$0.20
• Quarter ended Sep 30, 2024: revenue $12.5M (down 6.8% year over year), net income −$5.03M, EPS −$0.28
• Quarter ended Jun 30, 2024: revenue $15.1M (up 6.6% year over year), net income −$2.97M, EPS −$0.16
• Quarter ended Mar 31, 2024: revenue $14.4M (up 28.4% year over year), net income −$3.36M, EPS −$0.19
• Quarter ended Dec 31, 2023 (from the annual report): revenue $13.8M (up 7.2% year over year), net income −$5.57M, EPS −$0.31
• Quarter ended Sep 30, 2023: revenue $13.4M (down 8.9% year over year), net income −$5.42M, EPS −$0.31
• Quarter ended Jun 30, 2023: revenue $14.1M (up 85.9% year over year), net income −$5.01M, EPS −$0.28
• Quarter ended Mar 31, 2023: revenue $11.2M (up 8.0% year over year), net income −$7.69M, EPS −$0.44
• Quarter ended Dec 31, 2022 (from the annual report): revenue $12.8M (up 1.2% year over year), net income −$14.4M, EPS −$0.84
• Quarter ended Sep 30, 2022: revenue $14.7M (up 20.2% year over year), net income −$8.10M, EPS −$0.47
• Quarter ended Jun 30, 2022: revenue $7.61M (down 40.4% year over year), net income −$14.7M, EPS −$0.86
• Quarter ended Mar 31, 2022: revenue $10.4M (down 1.8% year over year), net income −$10.3M, EPS −$0.60
• Quarter ended Dec 31, 2021 (from the annual report): revenue $12.7M, net income −$7.05M, EPS −$0.40
• Quarter ended Sep 30, 2021: revenue $12.3M, net income −$7.18M, EPS −$0.42

XGN cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$13.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$13.3M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$14.5M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$32.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$20.3M, share buybacks n/a

XGN balance sheet

• Jun 30, 2026: cash $24.6M, total assets $51.9M, total liabilities $39.7M, shareholders' equity $12.2M, long-term debt $22.3M
• Mar 31, 2026: cash $21.5M, total assets $52.0M, total liabilities $37.5M, shareholders' equity $14.4M, long-term debt $22.3M
• Dec 31, 2025: cash $32.2M, total assets $58.0M, total liabilities $40.6M, shareholders' equity $17.4M, long-term debt $22.3M
• Sep 30, 2025: cash $35.7M, total assets $62.8M, total liabilities $44.7M, shareholders' equity $18.1M, long-term debt $22.3M
• Jun 30, 2025: cash $30.0M, total assets $58.8M, total liabilities $37.7M, shareholders' equity $21.0M, long-term debt $22.3M
• Mar 31, 2025: cash $11.2M, total assets $40.3M, total liabilities $33.9M, shareholders' equity $6.40M, long-term debt $18.4M
• Dec 31, 2024: cash $22.0M, total assets $44.7M, total liabilities $35.1M, shareholders' equity $9.54M, long-term debt $19.8M
• Sep 30, 2024: cash $22.0M, total assets $43.6M, total liabilities $30.7M, shareholders' equity $12.9M, long-term debt $19.8M

What is XGN's revenue?

EXAGEN INC reported $71.1M of revenue over its last four quarters, through June 30, 2026.

Is XGN profitable?

No. EXAGEN INC lost $18.9M over the last four quarters.

What is XGN's EPS?

Diluted earnings per share over the last four quarters were −$0.82; −$0.13 in the latest quarter.

XGN ownership and insider trades · All stocks